Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Goodwill (2023 - 2025)

Zevra Therapeutics' Goodwill history spans 3 years, with the latest figure at $4.7 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.02% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $4.7 million, changed 0.02%, while the annual FY2025 figure was $4.7 million, 0.02% changed from the prior year.
  • Goodwill reached $4.7 million in Q4 2025 per ZVRA's latest filing, roughly flat from $4.7 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $4.7 million in Q1 2024 to a low of $4.7 million in Q4 2023.
  • Average Goodwill over 3 years is $4.7 million, with a median of $4.7 million recorded in 2024.
  • Peak YoY movement for Goodwill: increased 0.02% in 2024, then fell 0.02% in 2025.
  • A 3-year view of Goodwill shows it stood at $4.7 million in 2023, then grew by 0.02% to $4.7 million in 2024, then fell by 0.02% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Goodwill are $4.7 million (Q4 2025), $4.7 million (Q3 2025), and $4.7 million (Q2 2025).